Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16836611 | 0.84 | ALDH1A1 (0.59) | LMNAALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL3339926 | 0.84 | ABCB1 (0.64) | LMNASMN1; SMN2ALDH1A1KDM4EABCB1 | |
| SCHEMBL16836610 | 0.83 | SLC6A3 (0.51) | LMNASMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL19604252 | 0.83 | ABCB1 (0.60) | ALDH1A1KDM4EABCB1KMT2APOLB | |
| SCHEMBL19564484 | 0.83 | ABCB1 (0.46) | LMNASMN1; SMN2ALDH1A1KDM4EABCB1 | |
| SCHEMBL28229749 | 0.83 | HTT (0.58) | LMNAKDM4EMAPTKMT2APOLB | |
| SCHEMBL19599252 | 0.82 | HCRTR2 (0.47) | LMNASMN1; SMN2ALDH1A1KDM4EABCB1 | |
| SCHEMBL24159369 | 0.80 | ABCB1 (0.43) | LMNASMN1; SMN2ALDH1A1KDM4EABCB1 | |
| SCHEMBL11180904 | 0.79 | ABCB1 (0.66) | LMNASMN1; SMN2ALDH1A1KDM4EABCB1 | |
| SCHEMBL19604247 | 0.79 | HCRTR2 (0.50) | ALDH1A1L3MBTL1TSHRHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3932923-B1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | UNIV CENTRAL CHINA NORMAL (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-3932923-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | Central China Normal University (CN) | 2022-01-05 | — | — | EP | disclosed |
| WO-2020187291-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREFOR | 华中师范大学 | 2020-09-24 | — | — | WO | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| WO-2016100157-A2 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | LMNA 3887/4885SMN1; SMN2 2618/4885ALDH1A1 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.